Drugmaker Leaves Lobbying Group After Price Controversy
- Marathon Pharmaceuticals is no a longer member of PhRMA
- PTC Therapeutics plans to give pricing info on May 4 earnings
Trump vs. Big Pharma: Can He Bring Drug Prices Down?
This article is for subscribers only.
Marathon Pharmaceuticals LLC left the drug industry’s main Washington lobbying group on Thursday, said two people familiar with the matter, after a controversy over the high price of its rare-disease drug.
Pharmaceutical Research and Manufacturers of America, or PhRMA, began reviewing its membership criteria after Marathon said in February that it would charge $89,000 a year for the drug Emflaza, generic versions of which were previously available to U.S. patients from overseas pharmacies for about $1,000. The move by closely-held Marathon drew criticism from patients, lawmakers and other members of the industry.